CTOs on the Move

Cybrexa

www.cybrexa.com

 
Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cybrexa.com
  • 5 Science Park 395 Winchester Avenue
    New Haven, CT USA 06511
  • Phone: 860.717.2731

Executives

Name Title Contact Details
Jaya Gautam
 Senior Vice President of Technical Operations Profile

Funding

Cybrexa raised $13.4M on 06/21/2019
Cybrexa raised $25M on 03/10/2021

Similar Companies

Affigen

Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.

Quench Bio

Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.

Pionyr Immunotherapeutics

Pionyr Immunotherapeutics discovers and develops first-in-class biologic drugs that fine-tune natural immune responses to increase immune defenses for diseases such as cancer, or to dampen immune responses in autoimmune diseases.

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.

Cadent Therapeutics

Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease.